-
VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER2025-04-17
-
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10529 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2025-04-15
-
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20122 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2025-04-07
-
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20108 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2025-04-07
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 20252025-04-02
-
FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 20242025-03-21
-
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 20242025-03-21
-
DATE OF BOARD MEETING2025-03-10
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE THIRD INDICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2025-03-10
-
VOLUNTARY ANNOUNCEMENT - THE SECOND BIOLOGICS LICENSE APPLICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2025-03-04
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 20252025-03-03
-
VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR OSTEOSARCOMA2025-02-25
